Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca32fd2a44fd326ffd027a75a57bd13f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d2e7fa9433e04fc27265b1d92b48e1d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1870024223df71c715c62d0edd723acb |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-74 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 |
filingDate |
2019-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4fe8da75ae306f08497d8aa15726033 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d23a5b00e9f7f8f929e1191d663b84f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb7cfe483b69d7c46695d9e68e61d5e8 |
publicationDate |
2020-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2020070062-A1 |
titleOfInvention |
Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma |
abstract |
Rhinovirus infections are the main cause of asthma exacerbations. As Natural Killer (NK) cells are important actors of the antiviral innate response, the inventors aimed to evaluate the functions of NK cells from severe asthmatic patients in response to rhinovirus or rhinovirus-like molecules. Peripheral blood mononuclear cells from severe asthmatic patients and healthy donors were stimulated with pathogen-like molecules or with the human rhinovirus A9 (HRV). NK cell activation, degranulation and IFN-γ expression were analyzed. The inventors found NK cells from severe asthmatic patients were less cytotoxic and expressed less IFN-γ than NK cells from healthy donors. NK cells from severe asthmatics exhibited an exhausted phenotype, with an increased expression of Tim-3. Finally, the inventors show that neutralization of Tim3 restores rhinovirus-induced NK cell activation. Together, the findings prompt to consider that Tim-3 inhibitors would be suitable for treating exacerbation in patients suffering from severe asthma. |
priorityDate |
2018-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |